Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 256-263

  Le Tourneau, Christophe ^a   Siu, Lillian L ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epidermal growth factor receptor; Head and neck cancer; Molecular targeted therapies; Predictive biomarker; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; METHOTREXATE; MOLECULAR THERAPY AGENT; PACLITAXEL; PLATINUM; SORAFENIB; VASCULOTROPIN;

CLINICAL STUDY; CLINICAL TRIAL; DRUG RESISTANCE; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 41949091830     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f9b575     Document Type: Review

References (44)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
2. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-2177.
3. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-7356.
4. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 14:295-304.
5. Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007; 96:408-416.
6. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298:70-82. This article is quite a complete review on the rationale and clinical results of anti-EGFR agents in HNSCC.
7. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
8. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. J Clin Oncol 2005; 23:5531.
9. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11:8418-8424.
10. Kirby AM, A'Hern RP, D'Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006; 94:631-636.
11. Stewart JSW, Cohen EEW, Licitra L, et al. A phase III randomized parallelgroup study of gefitinib (RESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck [abstract]. In: American Association for Cancer Research Annual Meeting: Proceedings; 14-18 Apr 2007; Los Angeles. Philadelphia: AACR; 2007. Abstract 3522.
12. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
13. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2006; 24:5568.
14. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997; 89:341-343.
15. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
16. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
17. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654.
18. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25:2178-2183.
19. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC) [abstract]. J Clin Oncol 2007; 25:6012.
20. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24:2866-2872.
21. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: results of a randomized phase III (Extreme) study [abstract]. J Clin Oncol 2007; 25:6091. This trial is the first to demonstrate a survival benefit by the addition of a molecular-targeted agent to standard platinum-based regimen in the first-line treatment of recurrent or metastatic HNSCC.
22. Buentzel J, de Vries A, Micke O. Experience with cetuximab plus paclitaxel/ carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol 2007; 25:6077.
23. Belón J, Irigoyen A, Rodríguez I, et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005; 23:5563.
24. Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]. J Clin Oncol 2007; 25:6013.
25. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-812.
26. Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer: more insights, but more questions. J Clin Oncol 2007; 25:2152-2155. This editorial provides a concise overview of the mechanisms involved in the antitumour activity of anti-EGFR agents in HNSCC.
27. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164-2170.
28. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176.
29. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25:2184-2190. This study shows that phosphorylated EGFR and EGFR gene amplification status by FISH may be further explored as molecular predictive biomarkers of sensitivity to anti-EGFR agents.
30. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006; 19:634-640.
31. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064-5073.
32. Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 2007; 18:761-767.
33. Lothaire P, de Azambuja E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006; 28:256-269.
34. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000; 18:155-161.
35. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 2005; 23:5504.
36. Karamouzis MV, Friedland D, Johnson R, et al. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis [abstract]. J Clin Oncol 2007; 25:6049.
37. Williamson SK, Moon J, Huang CH, et al. A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. J Clin Oncol 2007; 25:6044.
38. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773.
39. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2007 Oct 2 [Epub ahead of print].
40. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007; 96:952-959.
41. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/ mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13:4964-4973.
42. Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13:4291-4299.
43. Le Tourneau C, Faivre S, Siu LL. Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer 2007; 43:2457-2466.
44. Yun HJ, Bogaerts J, Awada A, Lacombe D. Clinical trial design limitations in head and neck squamous cell carcinomas. Curr Opin Oncol 2007; 19:210-215.